{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["11(6)"],"submitter":["Furtado LC"],"pubmed_abstract":["Gliomas are a type of brain tumor associated with poor patient prognosis, with current treatment, surgical resection when feasible, followed by radiotherapy and chemotherapy (Temozolomide), yielding a median survival of approximately 15 months. In light of the urgent need for more effective therapies, histone deacetylases (HDACs) have emerged as promising targets, given their differential expression across tumor types and disease grades. Although HDAC inhibitors are well established in the treatment of hematological malignancies, their potential is now being explored in solid tumors, including glioblastoma (GBM). In this study, hydroxamate-based (<b>3a</b>) and benzamide-based (<b>6a</b>) HDAC inhibitors were synthesized and evaluated in glioma cell lines and glioblastoma stem cells (GSC)."],"journal":["ACS omega"],"pagination":["10104-10120"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12917657"],"repository":["biostudies-literature"],"pubmed_title":["Repositioning HDAC Inhibitors for Glioma Treatment: Synthesis and Biological Evaluation."],"pmcid":["PMC12917657"],"pubmed_authors":["Furtado LC","Gouvea LM","Toledo MFZJ","Kronenberger T","Costa-Lotufo LV","Machado-Neto JA","Ferreira EG","Silva NATF","Parise Filho R","Waitman KB","Kruyt FAE"],"additional_accession":[]},"is_claimable":false,"name":"Repositioning HDAC Inhibitors for Glioma Treatment: Synthesis and Biological Evaluation.","description":"Gliomas are a type of brain tumor associated with poor patient prognosis, with current treatment, surgical resection when feasible, followed by radiotherapy and chemotherapy (Temozolomide), yielding a median survival of approximately 15 months. In light of the urgent need for more effective therapies, histone deacetylases (HDACs) have emerged as promising targets, given their differential expression across tumor types and disease grades. Although HDAC inhibitors are well established in the treatment of hematological malignancies, their potential is now being explored in solid tumors, including glioblastoma (GBM). In this study, hydroxamate-based (<b>3a</b>) and benzamide-based (<b>6a</b>) HDAC inhibitors were synthesized and evaluated in glioma cell lines and glioblastoma stem cells (GSC).","dates":{"release":"2026-01-01T00:00:00Z","publication":"2026 Feb","modification":"2026-07-16T17:59:50.719Z","creation":"2026-07-09T11:10:33.061Z"},"accession":"S-EPMC12917657","cross_references":{"pubmed":["41726712"],"doi":["10.1021/acsomega.5c11083"]}}